Biostage, Inc. (BSTG)
| Market Cap | 49.90M |
| Revenue (ttm) | 572 |
| Net Income (ttm) | -9.28M |
| Shares Out | 11.61M |
| EPS (ttm) | -0.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107 |
| Open | 4.30 |
| Previous Close | 4.30 |
| Day's Range | 4.30 - 4.30 |
| 52-Week Range | 1.12 - 6.80 |
| Beta | -0.42 |
| Analysts | Sell |
| Price Target | n/a |
| Earnings Date | May 16, 2022 |
About BSTG
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts. [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
No stock price forecast available yet.
News
Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
The current study tested the biomechanical strength of the newly regenerated esophageal tissue and demonstrated that the strength of the tissue was comparable to adjacent native tissue. HOLLISTON, Mass.
Biostage Reports Q1 2022 Financial Results and Corporate Highlights
HOLLISTON, Mass. , May 16, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating e...
Biostage Announces $5.1 Million Financing to Advance Clinical Trial
HOLLISTON, Mass. , May 13, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating eso...
Biostage Schedules Conference Call and Webcast for Q1 2022 Results
HOLLISTON, Mass., May 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating e...
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
Extends Core Intellectual Property coverage for treatment of lung cancer as well as esophageal cancer. HOLLISTON, Mass.
Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results
HOLLISTON, Mass. , April 1, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating...
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
HOLLISTON, Mass. , March 30, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treatin...
Biostage Announces "Meet the Founder, New Chairman and Interim CEO" Webinar
HOLLISTON, Mass., Jan. 25, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating...
Biostage Announces Court's Preliminary Injunction Order Requiring its Insurance Carrier to Continue Paying for Defense
HOLLISTON, Mass., Jan. 25, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating ...
New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets
HOLLISTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and F...
Biostage Hires David Green as Chief Executive Officer
HOLLISTON, Mass., Nov. 30, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and...
Biostage Reports Q3 2021 Financial Results
HOLLISTON, Mass., Nov. 15, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellfr...
Biostage™ Appoints Jerry He to Board of Directors and Completes Private Placement of $2.6 Million to Continue Its Cli...
HOLLISTON, Mass., Sept. 8, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing novel organ regeneration technology based its patented Cel...
Biostage Reports Q2 2021 Financial Results
HOLLISTON, Mass., Aug. 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellfr...
Biostage Reports Q1 2021 Financial Results
HOLLISTON, Mass., May 24, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellfra...
Biostage Reports 2020 Financial Results and Appointment of Interim Vice President of Finance
HOLLISTON, Mass., April 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing next-generation bioengineered esophageal implants, today a...